Last reviewed · How we verify
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak300)
The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).
Details
| Lead sponsor | Amgen |
|---|---|
| Phase | PHASE3 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 160 |
| Start date | Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu May 14 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Colorectal Cancer (CRC)
Interventions
- Sotorasib
- Panitumumab
- Trifluridine and Tipiracil
- Regorafenib
Countries
France, Italy, Japan, Greece, Taiwan, United Kingdom, Germany, Mexico, South Korea, Australia, United States, Spain